Sialic Acid Deposition Impairs the Utility of AAV9, but Not Peptide-modified AAVs for Brain Gene Therapy in a Mouse Model of Lysosomal Storage Disease-Reference-Cited by-同舟云学术

Sialic Acid Deposition Impairs the Utility of AAV9, but Not Peptide-modified AAVs for Brain Gene Therapy in a Mouse Model of Lysosomal Storage Disease

Published:2012-07 Issue:7 Volume:20 Page:1393-1399
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Chen Yong Hong,Claflin Kristin,Geoghegan James C,Davidson Beverly L

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference46 articles.

1. Fabry Disease: Perspectives from 5 Years of FOS;Fuller,2006

2. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells;Biffi;J Clin Invest,2004

3. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy;Cartier;Science,2009

4. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis;Xu;Mol Ther,2011

5. Enzyme replacement therapy for the mucopolysaccharide storage disorders;Kakkis;Expert Opin Investig Drugs,2002

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications;Advanced Drug Delivery Reviews;2024-08

2. Recombinant Adeno-Associated Virus Vectors for Gene Therapy of the Central Nervous System: Delivery Routes and Clinical Aspects;Biomedicines;2024-07-09

3. Anti-seizure gene therapy for focal cortical dysplasia;Brain;2023-12-15

4. Receptor–mediated transcytosis of macromolecules across the blood–brain barrier;Expert Opinion on Drug Delivery;2023-09-15

5. Anti-seizure Gene Therapy for Focal Cortical Dysplasia;2023-01-09